HBM Holdings Ltd. (HK:2142)
:2142
Want to see HK:2142 full AI Analyst Report?
2142 Stock Chart & Stats
HK$12.08
HK$0.18(8.04%)
At close: 4:00 PM EST
HK$12.08
HK$0.18(8.04%)
Day’s Range― - ―
52-Week RangeHK$7.52 - HK$17.98
Previous CloseN/A
Volume9.30M
Average Volume (3M)8.63M
Market Cap
HK$10.47B
Enterprise ValueHK$946.15M
Total Cash (Recent Filing)HK$401.90M
Total Debt (Recent Filing)HK$81.77M
Price to Earnings (P/E)13.5
Beta1.15
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding899,311,700
10 Day Avg. Volume6,681,047
30 Day Avg. Volume8,634,233
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.37
Price to Sales (P/S)7.82
P/FCF Ratio17.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$19.97Price Target Upside65.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.08
Revenue Forecast (FY)HK$230.28M
Bulls Say, Bears Say
Bulls Say
Strong 2025 ProfitabilityThe company delivered very high gross (~93%) and net (~58%) margins in 2025 alongside a large earnings rebound. Such margin expansion signals scalable economics and pricing power in core offerings, supporting durable cash generation and reinvestment capacity if revenue levels hold.
Improving Leverage And Balance SheetA materially lower debt-to-equity and a stronger equity base in 2025 materially enhance financial flexibility and reduce refinancing risk. Improved balance sheet health supports investment in growth, cushions cyclicality, and strengthens ability to sustain capex or M&A without compromising solvency.
Positive Operating And Free Cash FlowConversion of earnings into substantial operating and free cash flow shows the business can fund operations and returns internally. Durable positive FCF supports debt reduction, shareholder returns, or strategic reinvestment, improving long-term sustainability if cash generation persists.
Bears Say
Historical Earnings And Cash VolatilityPast multi-year swings in revenue, margins, and cash flow indicate the company’s results are sensitive to business-cycle, product adoption, or execution variability. This volatility raises execution risk that a single strong year may not persist, complicating forecasting and capital allocation.
Recent Revenue RetractionA prior year revenue decline despite the 2025 rebound shows demand or execution can reverse. Structural revenue consistency is critical for sustaining high margins and ROE; intermittent retractions suggest dependency on a few products or contracts and heighten risk to long-term margin durability.
Uneven Cash Flow History And Past Cash BurnPeriods of significant cash burn and negative operating/free cash flow demonstrate the firm's cash generation has been episodic. Such swings can limit ability to invest or service obligations during downturns and mean the 2025 positive FCF may require sustained execution to be deemed reliable.
HBM Holdings Ltd. News
2142 FAQ
What was HBM Holdings Ltd.’s price range in the past 12 months?
HBM Holdings Ltd. lowest stock price was HK$7.52 and its highest was HK$17.98 in the past 12 months.
What is HBM Holdings Ltd.’s market cap?
HBM Holdings Ltd.’s market cap is HK$10.47B.
When is HBM Holdings Ltd.’s upcoming earnings report date?
HBM Holdings Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 104 days.
How were HBM Holdings Ltd.’s earnings last quarter?
HBM Holdings Ltd. released its earnings results on Mar 30, 2026. The company reported HK$0.183 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.183.
Is HBM Holdings Ltd. overvalued?
According to Wall Street analysts HBM Holdings Ltd.’s price is currently Undervalued.
Does HBM Holdings Ltd. pay dividends?
HBM Holdings Ltd. does not currently pay dividends.
What is HBM Holdings Ltd.’s EPS estimate?
HBM Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HBM Holdings Ltd. have?
HBM Holdings Ltd. has 899,311,700 shares outstanding.
What happened to HBM Holdings Ltd.’s price movement after its last earnings report?
HBM Holdings Ltd. reported an EPS of HK$0.183 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.028%.
Which hedge fund is a major shareholder of HBM Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:2142
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HBM Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$19.97 (65.27% Upside)
HK$19.97 (65.27% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
928.57%
12-Months-Change
Fundamentals
Return on Equity
17.09%
Trailing 12-Months
Asset Growth
133.13%
Trailing 12-Months
Company Description
HBM Holdings Ltd.
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.
2142 Stock 12 Month Forecast
Average Price Target
HK$19.97
▲(65.27% Upside)
Technical Analysis
Alphamab Oncology
―
Lepu Biopharma Co. Ltd. Class H
―
Abbisko Cayman Limited
―
CStone Pharmaceuticals
―
Shandong Boan Biotechnology Company., Limited. Class H
―
Options Prices
Currently, No data available
---